Fucoidan Chondrogenesis Promoter for Cartilage Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for cartilage damage and diseases such as arthrosis and arthritis are inadequate in promoting cartilage repair and are often associated with side effects, necessitating the development of a safe and effective chondrogenesis promoter.
Innovation Solution
A chondrogenesis promoter comprising fucoidan, a polysaccharide from marine algae, with a molecular weight of 8,000 to 400,000, which promotes the production of glycosaminoglycan and proteoglycan, thereby facilitating cartilage repair and serving as a prophylactic or therapeutic agent for cartilage damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic agents (glucosamine, glucuronic acid) are used for cartilage damage, then some therapeutic effect is achieved, but side effects occur and cartilage repair promotion is insufficient
Solution Approach 1:
The patent changes the chemical parameter of the therapeutic agent by using fucoidan with specific molecular weight (8,000 to 400,000) and specific chemical structure (sulfated polysaccharide), which fundamentally alters the therapeutic profile to achieve cartilage repair promotion without the side effects of conventional agents
Solution Approach 2:
The patent extracts and utilizes the specific active component fucoidan from marine algae, separating it from the complex natural source to create a purified therapeutic agent that targets cartilage repair specifically without the unwanted effects of conventional synthetic or semi-synthetic agents
2Reliability
If fucoidan with molecular weight 8,000 to 400,000 is used, then chondrogenesis promotion is achieved, but molecular weight optimization is required for maximum efficacy
Solution Approach 1:
The patent optimizes the molecular weight parameter of fucoidan to the specific range of 8,000 to 400,000, which balances the biological activity (higher molecular weight provides better chondrogenesis promotion) with the absorption and distribution characteristics (lower molecular weight provides better bioavailability), achieving maximum therapeutic effect
Data Source
AI summary
Disclosed is a therapy which is for preventing or treating cartilage damage and diseases associated with cartilage damage, such as arthritides and osteoarthritis, and utilizes a more effective and more safe medicinal agent. Specifically disclosed are a cartilage production promoter, a glucosaminoglycan and/or proteoglycan production promoter, and a prophylactic or therapeutic agent for diseases associated with cartilage damage, each of which comprises fucoidan as an active ingredient.